NeuroPace, Inc. NPCE · Stock Open NeuroPace, Inc. in new tab
NeuroPace, Inc. Analysis (NPCE)
Is NeuroPace, Inc. a good investment? NeuroPace, Inc. (NPCE) is currently trading at 14.54 USD. Market analysts have a consensus price target of 20.22 USD. This suggests a potential upside from current levels.
Earnings Schedule: NeuroPace, Inc. is expected to release its next earnings report on Nov. 3, 2026. The market consensus estimate for Forward EPS is -0.22.
Investor FAQ
Does NeuroPace, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is NeuroPace, Inc.?
NeuroPace, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 3, 2026. The company currently has a trailing EPS of -0.47.
Company Profile
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Community Discussion